1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Merck inks latest immuno-oncology collab with Syndax

 
• By Lisa LaMotta

Merck & Co has inked another combination deal for its ultra-hot PD-1 inhibitor Keytruda (pembrolizumab); this time with Waltham, Mass.-based biotech Syndax Pharmaceuticals. The big pharma has placed significant emphasis on the success of Keytruda, which dominates the company's pipeline.

The pair announced the research collaboration on 31 March, but did not disclose financial details. The deal will combine the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.